Median overall survival when HMA were used upfront was 13.0 months (95%CI: 8.4–24.1), and 9.6 months (95%CI: 5.7–16.3) when used as second-line therapy or more for R/R CBF-AML. Here, CEBPZ is linked to acute myeloid leukemia.